RE:The wheels are in motion. Aphria has a big head start for global medical and will be #1 in Germany with their lowest cost production facilities and quality flower strains. Aphria's revenue is increasing, while production costs are going down, and will be cash flow positive and not losing money like ACB/WEED. Consumption is going up in Canada and Germany, EU & LATAM expansion is underway.